keyword
MENU ▼
Read by QxMD icon Read
search

ALCL

keyword
https://www.readbyqxmd.com/read/28342276/primary-cutaneous-anaplastic-large-cell-lymphoma
#1
REVIEW
Ryanne A Brown, Sebastian Fernandez-Pol, Jinah Kim
Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease.[1] CD30+ LPDs comprise approximately 25-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T cell neoplasm of the skin behind mycosis fungoides (MF).
March 25, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28340874/management-of-anaplastic-large-cell-lymphoma
#2
REVIEW
Dai Chihara, Michelle A Fanale
Anaplastic large cell lymphoma (ALCL) is one of the most common peripheral T-cell lymphomas, and the incidence is higher in blacks than non-Hispanic whites. ALK-positive and ALK-negative ALCL are distinct subtypes that have different characteristics and clinical outcomes. Breast implant-associated ALCL is a rare lymphoma that has a good survival outcome, and a recent study showed that total capsulectomy is essential for treatment. Brentuximab vedotin (BV) is a standard treatment for relapsed/refractory ALCL...
April 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28331364/silicone-induced-granuloma-of-breast-implant-capsule-sigbic-similarities-and-differences-with-anaplastic-large-cell-lymphoma-alcl-and-their-differential-diagnosis
#3
REVIEW
Eduardo de Faria Castro Fleury, Milena Morais Rêgo, Luciana Costa Ramalho, Veronica Jorge Ayres, Rodrigo Oliveira Seleti, Carlos Alberto Pecci Ferreira, Decio Roveda
Primary breast lymphoma is a rare disease and accounts for 0.5% of cases of breast cancer. Most primary breast lymphomas develop from B cells, and the involvement of T cells is rare. Anaplastic large cell lymphoma (ALCL) is a recently discovered T-cell lymphoma associated with breast implants. Only a few cases have been reported to date. It is believed that the incidence of ALCL is increasing because of the increasing number of breast implants. The clinical presentation is variable and can manifest as a palpable mass in the breast or armpit, breast pain, or capsular contracture...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28331184/the-long-non-coding-rna-linc01013-enhances-invasion-of-human-anaplastic-large-cell-lymphoma
#4
I-Hsiao Chung, Pei-Hsuan Lu, Yang-Hsiang Lin, Ming-Ming Tsai, Yun-Wen Lin, Chau-Ting Yeh, Kwang-Huei Lin
Anaplastic large-cell lymphoma (ALCL) is a rare type of highly malignant, non-Hodgkin lymphoma (NHL). Currently, only studies on the chimeric oncogene NPM-ALK have reported a link to ALCL progression. However, the specific molecular mechanisms underlying the invasion of ALCL are still unclear. Here, we sought to investigate differentially expressed, long non-coding RNAs (lncRNAs) in ALCL and their potential biological function. Our microarray analyses revealed that LINC01013, a novel non-coding RNA gene, was highly expressed in clinical specimens of ALCL and was significantly upregulated in invasive ALCL cell lines...
March 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28329586/cd30-lymphoproliferative-disorder-in-a-patient-with-metastatic-papillary-thyroid-carcinoma
#5
Jeremy Udkoff, Philip R Cohen
Background CD30+ lymphoproliferative disorders are rare and may feature a wide variety of presentations that mimic other conditions. Purpose A man with metastatic papillary thyroid carcinoma to skin who subsequently developed cutaneous anaplastic large cell lymphoma is described. Methods The PubMed medical database was used to search the following terms separately and in combination: ALCL, anaplastic large cell lymphoma ALCL, cutaneous anaplastic large cell lymphoma CALCL, cutaneous t-cell lymphoma CTCL, large t-cell lymphoma LTCL, lymphoproliferative, lymphomatoid papulosis LyP, mimic, papillary, thyroid cancer...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329531/skin-limited-relapse-of-systemic-anaplastic-large-cell-lymphoma
#6
Joshua A Farhadian, Vitaly Terushkin, Shane A Meehan, Craig Kornreich
Anaplastic large-cell lymphomas (ALCLs) are agroup of CD30-positive non-Hodgkin lymphomasthat are linked by common morphologic andimmunophenotypic features but have varyingclinical and genetic characteristics. The World HealthOrganization classification currently recognizes threesubtypes of ALCL: systemic anaplastic lymphomakinase-positive ALCL, systemic anaplastic lymphomakinase-negative (ALK-) ALCL, and primary cutaneousALCL. Here we present a 42-year-old man with ahistory of systemic ALK- ALCL, who was in remissionfor six months before relapsing with skin-limitedanaplastic large-cell lymphoma...
December 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28273702/-diagnosis-and-treatment-of-anaplastic-large-cell-lymphoma-in-children-and-adolescents-a-retrospective-multicenter-survey-study
#7
(no author information available yet)
Objective: To provide a descriptive review and improve our understanding of the clinical characteristics and treatment outcome of pediatric anaplastic large cell lymphoma (ALCL) in China. Method: The clinical data and outcomes of patients under 16 years of age with newly histopathologically-confirmed ALCL in 10 large single institutions in China between January 2009 and June 2014, were retrospectively analyzed.The event-free survival (EFS) was analyzed by the Kaplan-Meier method.The risk factors of disease progression or relapse were evaluated by logistic regression analysis...
March 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/28247950/use-of-brentuximab-vedotin-as-salvage-therapy-pre-allogeneic-stem-cell-transplantation-in-relapsed-refractory-cd30-positive-lympho-proliferative-disorders-a-single-centre-experience
#8
Heshani Mediwake, Kirk Morris, Cameron Curley, Jason Butler, Glen Kennedy
AIM: To assess the outcome of use of brentuximab as a bridge to allogeneic stem cell transplant (SCT) in patient with relapsed / refractory CD30+ classic Hodgkin Lymphoma c(HL) and Anaplastic Large Cell Lymphoma (ALCL). METHODS: Outcomes of consecutive patients with relapsed / refractory cHL / ALCL treated with brentuximab as a bridge to SCT were determined by retrospective review of individual medical records. Survival analysis was measured from start of brentuximab treatment...
March 1, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28157770/global-adverse-event-reports-of-breast-implant-associated-alcl-an-international-review-of-40-government-authority-databases
#9
Dhivya R Srinivasa, Roberto N Miranda, Arminder Kaura, Ashleigh M Francis, Antonella Campanale, Rosaria Boldrini, Janette Alexander, Anand Deva, Paula Gravina, L Jeffrey Medeiros, Karen Nast, Charles E Butler, Mark W Clemens
BACKGROUND: An estimated 200 patients have been reported with breast implant associated anaplastic large cell lymphoma (BI-ALCL), a rare T-cell lymphoma developing around breast prostheses. The purpose of this study was to review federal database submissions relating to BI-ALCL in 37 countries representing the majority of breast implant markets worldwide with available adverse event reporting. METHODS: Database queries were performed for Australia, Brazil, Canada, China, Columbia, Japan, Mexico, National Competent Authorities of the European Member States, New Zealand, South Korea, and United States...
January 20, 2017: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28157769/united-states-epidemiology-of-breast-implant-associated-anaplastic-large-cell-lymphoma
#10
Erin L Doren, Roberto N Miranda, Jesse C Selber, Patrick B Garvey, Jun Liu, L Jeffrey Medeiros, Charles E Butler, Mark W Clemens
BACKGROUND: Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a distinctive type of T-cell lymphoma that arises around breast implants. Although rare, all cases of BI-ALCL with adequate history have involved a textured breast implant. The objective of this study is to determine the United States incidence and lifetime prevalence of BI-ALCL in women with textured breast implants. METHODS: This is a retrospective review of documented cases of BI-ALCL in the United States from 1996 to 2015...
January 20, 2017: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28153507/expression-of-p63-protein-in-anaplastic-large-cell-lymphoma-implications-for-genetic-subtyping
#11
Xueju Wang, Rebecca L Boddicker, Surendra Dasari, Jagmohan S Sidhu, Marshall E Kadin, William R Macon, Stephen M Ansell, Rhett P Ketterling, Karen L Rech, Andrew L Feldman
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas that bear chromosomal rearrangements of the TP53 homologue, TP63, in a subset of cases that demonstrate aggressive clinical behavior. In the present study, we examined the relationship between p63 protein expression by immunohistochemistry and the results of fluorescence in situ hybridization (FISH) using TP63 probes in 116 ALCLs. We also determined the relative expression of full-length TAp63 and truncated ΔNp63 isoforms (e...
January 30, 2017: Human Pathology
https://www.readbyqxmd.com/read/28061468/the-heterogeneous-landscape-of-alk-negative-alcl
#12
Elisabetta Mereu, Elisa Pellegrino, Irene Scarfò, Giorgio Inghirami, Roberto Piva
Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients...
January 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28050598/alk-a-tyrosine-kinase-target-for-cancer-therapy
#13
REVIEW
Vijaykumar R Holla, Yasir Y Elamin, Ann Marie Bailey, Amber M Johnson, Beate C Litzenburger, Yekaterina B Khotskaya, Nora S Sanchez, Jia Zeng, Md Abu Shufean, Kenna R Shaw, John Mendelsohn, Gordon B Mills, Funda Meric-Bernstam, George R Simon
The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL). Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC. In other tumors, ALK copy-number gains and activating ALK mutations have been described. Dramatic and often prolonged responses are seen in patients with ALK alterations when treated with ALK inhibitors...
January 2017: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/28032129/first-dose-and-steady-state-pharmacokinetics-of-orally-administered-crizotinib-in-children-with-solid-tumors-a-report-on-advl0912-from-the-children-s-oncology-group-phase-1-pilot-consortium
#14
Frank M Balis, Patrick A Thompson, Yael P Mosse, Susan M Blaney, Charles G Minard, Brenda J Weigel, Elizabeth Fox
PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer. METHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first dose (n = 15) or at steady state (n = 49). Dose levels studied were 100, 130, 165, 215, 280 and 365 mg/m(2)/dose administered twice daily. Two capsule and two oral liquid formulations were used over the course of the trial...
January 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28013563/pax-5-positivity-in-anaplastic-lymphoma-kinase-negative-anaplastic-large-cell-lymphoma
#15
Indu Arun, Paromita Roy, Neeraj Arora, Saurabh Jayant Bhave, Reena Nair, Mammen Chandy
Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a subtype of T-cell lymphomas that may mimic several other malignancies morphologically. With the help of immunohistochemistry, most cases of ALCL can be diagnosed on the basis of expression of T-cell lineage associated antigens. However, aberrations in the expression of immunohistochemical markers pose diagnostic challenges. The morphological and immunophenotypic features of ALCL show considerable overlap with classical Hodgkin lymphoma (CHL), which is a B-cell lymphoma...
December 1, 2016: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28003677/two-relapsed-stage-iii-childhood-anaplastic-large-cell-lymphoma-patients-with-npm-alk-fusion-in-bone-marrow-from-initial-diagnosis
#16
Yui Kanazawa, Yuka Yamashita, Mitsuhiro Fujiwara, Michiko Muraoka, Kana Washio, Kiichiro Kanamitsu, Hisashi Ishida, Takae Nakano, Miho Yamada, Keizo Horibe, Takehiro Tanaka, Tadashi Yoshino, Akira Shimada
Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10-30% of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60-75 disease-free survival; however, a relatively high relapse rate was observed (25-30% ). We report 2 patients with Stage III ALCL who relapsed 6-18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients...
December 2016: Acta Medica Okayama
https://www.readbyqxmd.com/read/28003232/anaplastic-large-cell-lymphoma-masquerading-as-osteomyelitis-of-the-shoulder-an-uncommon-presentation
#17
Matthew Tuck, Jane Lim, Jose Lucar, Debra Benator
The presentation of anaplastic lymphoma kinase protein (ALK)-negative anaplastic large cell lymphoma (ALCL) in bone is rare. We describe a patient with ALK-negative ALCL presenting with clinical and radiographic findings suggesting osteomyelitis 6 months after left rotator cuff repair surgery. A review of the characteristics of ALK-negative ALCL with primary bone involvement is presented. ALCL should be considered in patients not responding to therapies for osteomyelitis.
December 21, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27995879/-comparison-of-allogeneic-or-autologous-hematopoietic-stem-cell-transplant-for-high-risk-peripheral-t-cell-lymphomas
#18
Q L Wang, H W Huang, Z M Jin, X W Tang, H Y Qiu, C C Fu, Y Han, M Miao, H R Chang, A N Sun, D P Wu
Objective: To evaluate the efficacy of auto-HSCT and allo-HSCT in the treatment of high risk peripheral T cell lymphoma (PTCL). Methods: From July 2007 to July 2014, 60 cases of high risk PTCL were analyzed retrospectively. Results: All 60 patients were at high risk group (carried with IPI≥3), with a median age of 31 (12-58) years old. Of the 60 cases, 22 were PTCL-not otherwise specified (PTCL-NOS), 22 ALK negative anaplastic large cell lymphoma (ALK-negative ALCL) and 16 angioimmunoblastic T-cell lymphoma (AITL)...
November 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27968935/cutaneous-lymphoma-kids-are-not-just-little-people
#19
Katalin Ferenczi, Hanspaul S Makkar
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous lymphoma in childhood is rare, but it can present as early as the first decade of life. In both adults and children, the diagnosis of cutaneous lymphoma can be challenging because inflammatory dermatoses can mimic CTCL both clinically and histologically. The clinicopathologic manifestations can be similar in adults and younger individuals; however, differences in the prevalence of certain CTCL variants among age groups exist...
November 2016: Clinics in Dermatology
https://www.readbyqxmd.com/read/27930548/primary-central-nervous-system-alk-positive-anaplastic-large-cell-lymphoma-in-an-adult-a-rare-case-report
#20
Xiaoqin Dong, Jun Li, Na Huo, Yan Wang, Zhao Wu, Xiaohong Lin, Hong Zhao
RATIONALE: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin lymphoma. It mostly invades lymph nodes with extranodal involvement observed in the soft tissue, bone, and skin. PATIENT CONCERNS: We report a 34-year-old Chinese male patient who presented with headache, diplopia, and vomit. Cerebrospinal fluid (CSF) analysis via lumbar puncture showed elevated CSF pressure, elevated CSF protein concentrations, decreased CSF glucose and chloride concentration significantly, and pleocytosis of 68 to 350 × 10/L, in which lymphocytes and monocytes were predominant...
December 2016: Medicine (Baltimore)
keyword
keyword
105270
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"